

**HiWATE**  
**WP Discussions**  
**22 February 2010**  
**London**

Imperial College London 170 Queen's Gate, London, SW7 5HF

170 Queen's Gate	Programme - Day 1	Speakers
09.00 - 09.15	Registration	
09.15 - 09.30	Welcome	Mark Nieuwenhuijsen, <i>Project Coordinator</i> Laurence Moreau, <i>European Commission Project Officer</i>
09.30 - 10.30	WP 1 DBP measurements	Stuart Krasner, <i>Metropolitan Water District of Southern California</i> Maria Karadaneli, <i>UA</i> Panu Rantakokko, <i>THL</i> Euripides Stephanou, <i>CRG</i>
10.30 - 11.00	WP 2 DBP modelling	James Bennett, <i>IMPERIAL</i>
11.00 - 11.45	WP 3 Still birth, birth weight and congenital anomalies	Elena Righi, <i>UNIMORE &amp;</i> Mireille Toledano, <i>IMPERIAL</i>
11.45 - 12.15	Refreshment break	
12.15 - 12.45	WP 4 Birth cohorts	Manolis Kogevinas, <i>UoC</i>
12.45 - 13.15	WP 5 Semen quality	Nina Iszatt, <i>IMPERIAL</i>
13.15 - 14.15	Lunch	
14.15 - 14.45	WP 6 Bladder cancer re-analysis	Sylvaine Cordier, <i>INSERM</i>
14.45 - 15.15	WP 7 Colon cancer study	Cristina Villanueva, <i>FIMIM</i>
15.15 - 16.00	WP 8 Risk assessment	Päivi Meriläinen, <i>THL</i>
16.00 - 16.30	Refreshment break	
16.30 - 17.00	WP 9 Technologies and Best Practice	Tom Bond, Radu Rautiu, <i>ICON</i>
17.00 - 17.30	WP 10 Review and Policy Implications	Mireille Toledano, <i>IMPERIAL</i>
17.30- 18.15	General discussion	
18.45	Drinks reception	
19.00	Dinner	

**HiWATE  
OPEN DAY  
23 February 2010  
London**

NATURAL HISTORY MUSEUM, CROMWELL ROAD, LONDON, SW7 5BD

<b>Flett Theatre</b>	<b>Programme - Open Day</b>	<b>Speakers</b>
08:45 - 09:05	Registration <i>Flett Foyer</i>	
09.05 - 09.20	Welcome & Introduction  <i>Chair: Howard Weinberg, UNC, USA</i>	Mark Nieuwenhuijsen, <i>Project Coordinator</i>
09.20 - 10.00	Emerging DBPs	Susan Richardson, <i>U.S EPA</i>
10.00 - 10.40	DBP occurrence and formation	Stuart Krasner, <i>Metropolitan Water District of Southern California</i>
10.40 - 11.10	Refreshment break <i>Flett Foyer</i>  <i>Chair: Manolis Kogevinas, University of Crete</i>	
11.10 - 11.50	Mammalian cell toxicology of emerging DBPs.	Michael Plewa, <i>University of Illinois (U.S.A.)</i>
11.50- 12.30	Mechanisms of toxicity and mixture effects	Jane Ellen Simmons, <i>U.S EPA</i>
12.30 - 13.30	Lunch <i>Flett Foyer</i>  <i>Chair: Elena Righi, UNIMORE</i>	
13.30 - 14.10	The epidemiology of DBPs and still birth	Mireille Toledano, <i>IMPERIAL</i>
14.10 - 14.50	The epidemiology of DBPs and prematurity and birth weight	Manolis Kogevinas, <i>UoC</i>
14.50 - 15.20	Refreshment break <i>Flett Foyer</i>  <i>Chair: Sylvaine Cordier, INSERM</i>	
15.20 - 16.00	The epidemiology of DBPs and colon cancer	Cristina Villanueva, <i>FIMIM</i>
16.00 - 16.40	Risk benefit assessment of microbial contamination and DBPs	Päivi Meriläinen, <i>THL</i>
16.40 - 17.00	Wrap up discussion	
17.00	Drinks & canapés reception <i>Flett Foyer</i>	<i>courtesy of IC Consultants Ltd</i>
19.00	Dinner <i>58 Prince's Gate</i>	

**HiWATE**  
**Implications & Recommendations**  
**24 February 2010**  
**London**

Imperial College London 170 Queen's Gate, London, SW7 5HF

170 Queen's Gate	Programme - Day 3	Speakers
09.00 - 09.30	Recap of the previous days	Mark Nieuwenhuijsen, <i>Project Coordinator</i>
09.30 - 10.30	Findings, Implications and Recommendations for DBP occurrence research - What do we know so far? - What implications does it have? - What should be further investigated? - What would be good DBP markers for epidemiological studies and risk assessment studies?	Discussion leader: Stuart Krasner, <i>Metropolitan Water District of Southern California</i> Rapporteur: Pannu Rantakokko, <i>THL</i>
10.30 - 11.00	Refreshment break	
11.00 - 12.00	Findings, Implications and Recommendations for DBP reproductive epidemiology research - What do we know so far? - What implications does it have? - How do the epidemiological and toxicological data and outcomes compare? - What should be further investigated?	Discussion leader: Manolis Kogevinas, <i>UoC</i> Rapporteur: Elena Righi, <i>UNIMORE</i>
12.00 - 13.00	Findings, Implications and Recommendations for DBP cancer epidemiology research - What do we know so far? - What implications does it have? - How do the epidemiological and toxicological data and outcomes compare? - What should be further investigated?	Discussion leader: Ken Cantor, <i>NIH</i> Rapporteur: Sylvaine Cordier, <i>INSERM</i>
13.00 - 14.00	Lunch	
14.00 - 15.00	Risk assessment, management and policy - How should risk assessment and management proceed? - What further data are needed? - What are the policy implications?	Discussion leader: Mark Nieuwenhuijsen, <i>Project Coordinator</i> Rapporteur: Päivi Meriläinen, <i>THL</i>
15.00 - 15.30	Refreshment break	
15.30 - 16.30	RPC meeting <i>Conclusions; project extension; extra sampling</i>	
16.30 - 17.30	WP 9 & WP10 meeting	
18.30	Dinner, tba	